When should aspirin be used for prevention of cardiovascular events?

JAMA - Journal of the American Medical Association

Volumn 312, Issue 23, 2014, Pages 2503-2504

  Gaziano, J Michael ^a   Greenland, Philip ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; EDITORIAL; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDICAL RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PUBLISHING; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT INDICATION; CARDIOVASCULAR DISEASES; FEMALE; MALE; MYOCARDIAL INFARCTION;

ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84919341043     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.16047     Document Type: Editorial

References (10)

1. Second International Study of Infarct Survival Collaborative Group (ISIS-2). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet. 1988;2(8607):349-360.
2. Antithrombotic Trialists' Collaboration. Collaborativemeta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324(7329):71-86.
3. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313-316.
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-135.
5. Baigent C, Blackwell L, Collins R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease. Lancet. 2009;373(9678):1849-1860.
6. Bartolucci AA, TenderaM, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107(12):1796-1801.
7. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors. JAMA. doi:10.1001/jama .2014.15690.
8. ASCEND. https://clinicaltrials.gov/ct2/show/NCT00135226?term=ascend+aspirin&rank=1. Accessed October 9, 2014.
9. ARRIVE. https://clinicaltrials.gov/ct2/show/NCT00501059?term=ARRIVE+aspirin&rank=1. Accessed October 9, 2014.
10. Aspirin in Reducing Events in the Elderly (ASPREE). http://clinicaltrials.gov/ct2/show/NCT01038583?term=ASPREE+aspirin&rank=2. Accessed November 11, 2014.